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ABSTRACT
Monanchocidin A (MonA) is a novel alkaloid recently isolated from the marine 
sponge Monanchora pulchra. The compound reveals cytotoxic activity in genitourinary 
cancers including cisplatin-sensitive and -resistant germ cell tumor (GCT) cell lines, 
hormone-sensitive and castration-resistant prostate carcinoma cell lines and different 
bladder carcinoma cell lines. In contrast, non-malignant cells were significantly 
less sensitive. MonA is highly synergistic with cisplatin in GCT cells. Induction of 
autophagy at lower and lysosomal membrane permeabilization (LMP) at higher 
concentrations were identified as the dominating modes of action. Cytotoxicity and 
protein degradation could be inhibited by 3-methyladenine, an inhibitor of autophagy. 
LMP was confirmed by loss of acridine orange staining of lysosoms and by release of 
cathepsin B. In conclusion, MonA exerts cytotoxiс activity by mechanisms different 
from “classical” apoptosis, and could be a promising new compound to overcome 
resistance to standard therapies in genitourinary malignancies.
INTRODUCTION
Development of resistance to standard treatment 
regimens is a major challenge in the course of oncological 
therapy. Although germ cell tumors (GCT) are highly 
sensitive towards platin-based cytotoxic therapies [1], 
30-40% of patients with high risk metastatic disease 
fail to achieve a long-term response due to primary or 
secondary cisplatin resistance [2]. Insufficient induction 
of apoptosis seems to play a major role in cisplatin 
resistance (for review see [3, 4]). In prostate cancer, 
patients will inevitably succumb to the disease because 
of the development of resistance to treatment. Loss of 
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efficacy of androgen deprivation therapy by up-regulation 
or mutation of the androgen receptor, development of 
resistance to docetaxel mediated by different mechanisms, 
e.g. up-regulation of anti-apoptotoc protein Bcl-2 [5], and 
resistance to abiraterone and enzalutamid mediated by 
androgen-receptor splice variants have been associated 
with disease progression [6-8]. Standard of care for 
patients with advanced or metastatic urothelial cancer are 
platin-based chemotherapy regimens. However, only 50% 
respond to this therapy, and more than 80% of the patients 
do not achieve long term remissions [9]. Thus, new 
drugs with different mechanisms of action to overcome 
resistance to standard therapies are urgently needed.
A relevant percentage of cytotoxic drugs have 
been developed on the basis of natural compounds and 
their derivatives [10, 11]. Remarkably, the chemical 
structures and variety of natural compounds found in 
marine organisms differ significantly from terrestrial 
plants and animals. Specific environmental conditions 
such as high pressure and salt content as well as varying 
pH values of the sea have been identified as possible 
reasons. In addition, many organisms living in the highly 
competitive environment of the sea have developed special 
defense strategies to protect themselves against enemies. 
Often, they produce a large variety of small molecular 
substances with specific bioactive characteristics. Not 
surprisingly, these substances moved into the focus of 
cancer research in the past decades. Indeed, marine drugs 
such as cytarabin (Ara-C), trabectedin, and eribulin are 
used clinically to treat different malignancies including 
leukemias, lymphomas, soft tissue sarcomas, and breast 
cancer [10-14]. Monanchocidin A (MonA, Fig. 1A) is a 
novel alkaloid, initially isolated from the marine sponge 
Monanchora pulchra in 2010 [15]. It reveals cytotoxic 
activity against THP-1, HL-60, and HeLa human cancer 
cell lines at micro- and nanomolar concentrations. 
However, the precise mechanism of anticancer action has 
not been elucidated to date. 
In this study, we characterize the cytotoxic efficacy 
and the mode of action of this marine compound in human 
genitourinary cancer cell lines with defined levels of 
resistance against classical anti-tumor treatments such as 
androgen-deprivation, docetaxel, or cisplatin.
RESULTS
MonA is more active against cancer cells than 
against non-malignant cells
Cytotoxic activity of MonA (Fig. 1A) was evaluated 
in human cancer cells and non-malignant human cells by 
MTT assay and trypan blue assay. Remarkably, GCT, 
prostate cancer, and bladder cancer cell lines were found 
to be equally and highly sensitive to MonA (including 
androgen-independent PC3 and DU145 cells), while non-
malignant cells were affected to a lower extend (Fig. 1B, 
1C; Table 1). 
MonA is equally cytotoxic against cisplatin-
sensitive and -resistant GCT cells
To determine the efficacy of MonA in cisplatin-
resistant GCT, the compound was examined in human 
Table 1: IC50 of MonA and cisplatin in non-malignant cell lines and urogenital cancer cell lines after 72 h of 
treatment determined with MTT assay.
 MonA
Non-malignant cell lines Cisplatin-sensitive GCT cells
Cisplatin-resistant GCT
cells
Cell
line MRC-5 MRC-9 HEK 293T HUVEC NCCIT 2102EP TCam-2 NCCIT-R 2102EP-R
IC50,
µM 0.756 0.708 0.670 0.838 0.210 0.341 0.440 0.253 0.306
MonA
Prostate cancer cells Bladder cancer cells
Cell line PC3 DU145 LNCaP RT112 RT4 486p T24
IC50, µM 0.420 0.482 0.265 0.263 0.58 0.273 0.413
Cisplatin
Cisplatin-sensitive GCT cells Cisplatin-resistant GCT cells Bladder cancer cells
Cell 
line NCCIT 2102EP TCam-2 NCCIT-R 2102EP-R RT112 RT4 486p T24
IC50, 
µM 1.56 0.644 2.48 8.93 4.93 8.99 11.87 20.79 9.07
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GCT cell lines and cisplatin-resistant sublines. The cell 
lines NCCIT-R and 2102EP-R exhibit resistance to 
cisplatin in comparison to the original cell lines they have 
been generated from (Fig. 1B; Table 1) [16, 17]. MonA 
was equally cytotoxiс in all cancer cell lines. The level 
of cisplatin resistance had no impact on the efficacy of 
MonA (Fig. 1B; Table 1). Cytotoxicity was time- and 
dose-dependent. After 48 h of treatment, the IC50 ranged 
between 0.5 to 1 µM (Fig. 1D, 1E, data for NCCIT-R 
cells). Interestingly, activity of cisplatin could be enhanced 
by MonA. In fact, the combination treatment resulted in 
strong synergistic effects in NCCIT-R cells (Fig. 1F). 
Notably, the androgen-independent prostate cancer cells 
PC3 and DU145 were equally sensitive to MonA as 
GCT cells, while androgen-dependent LNCaP cells were 
even more sensitive (Table 1). Furthermore, bladder 
cancer cells, being even more resistant to cisplatin then 
cisplatin-resistant GCT cells, were as sensitive to MonA 
as other cancer cell lines (Fig. 1B; Table 1). For further 
investigations of the mode of action, the cisplatin-resistant 
NCCIT-R cell line was chosen as an example of a cell line 
resistant to standard chemotherapy.
Effects of MonA on cell cycle progression and 
induction of programmed cell death
After 24 h cell cycle analysis of NCCIT-R 
cells treated with MonA revealed a S-phase arrest 
at non-cytotoxic, and a G1-phase arrest at cytotoxic 
concentrations of MonA (Fig. 2A). Hallmarks of classical 
apoptosis e.g. cleaved PARP- and caspase-3 (Fig. 2B, 2C) 
were detected by Western blotting analyses in a time- and 
dose-dependent manner. Induction of caspase-3-cleavage 
was confirmed by flow cytometry using a PE-conjugated 
antibody against cleaved caspase-3 (Fig. 2D). Time- and 
dose-dependent phosphatidylserine externalization as well 
Figure 1: Effect of MonA on the viability of urogenital cancer cells and normal cells. NCCIT and NCCIT-R cells were treated 
with MonA as described in Materials and Methods. A, The structure of Monanchocidin A (MonA). B, IC50 of MonA and cisplatin for several 
lines of non-malignant human cell lines as well as GCT, prostate carcinoma and bladder carcinoma cell lines after 72 h of treatment. The 
values are shown in Table 1. C, Percentage of alive cells after treatment with 1 µM of MonA, determined by the trypan blue based viability 
assay. D, IC50 of MonA determined by the MTT assay. E, Trypan blue based viability assay. NCCIT and NCCIT-R cells were treated with 
MonA for 48 h. Time- and dose-dependent effects of MonA on NCCIT-R cells were examined by trypan blue based viability assay. n.s.: not 
significant. F, Effect of MonA in combination with cisplatin on NCCIT-R cells, examined by the MTT assay. Cells were co-treated with 
different concentrations of the single substances or their combination for 48 h at a constant molar ratio. The combinational index (CI) values 
were calculated with CompuSyn software. The ratio of the substances is C(MonA) : C(cisplatin) = 1.2 : 10.
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Figure 2: Effect of MonA on cell cycle distribution and induction of apoptosis. Cells were treated with MonA as described 
in Materials and Methods. A, Cell cycle analysis of NCCIT-R cells treated with 0.5 μM and 4 μM of MonA for 24 h after cell cycle 
synchronization by 0.1% FBS/DMEM. Cell cycle phase distribution was analyzed and quantified using the FlowJo software. B, C, Western 
blotting analysis of protein extracts of NCCIT-R cells treated with MonA for 48 h with different concentrations (B), or for different 
timespans with 1 µM (C). NCCIT-R cells treated with 10 μM of cisplatin (CP) for 48 h were used as positive controls for induction of 
apoptosis. Note that the weak signal observed in the bands of the loading control α-tubulin at the highest concentrations of MonA reflects 
protein degradation, and not unequal protein loading of the bands. D, To determine the percentage of cells containing activated caspase-3, 
NCCIT-R cells were treated with 0.5 µM (dashed area), or 1 µM of MonA (bold dashed area), or DMSO (control, gray area), and stained 
with antibodies against cleaved caspase-3; or treated with DMSO and stained with isotype control (dotted area). The amount of cleaved 
caspase-3 positive cells was quantified using Cell Quest Pro software. The graph shows the percentage of positive cells of the total cell 
number in each sample. E, Flow cytometry analysis of NCCIT-R cells treated with MonA: Annexin-V-FITC versus PI (double staining). 
Apoptotic cells appearing in the right lower and upper quadrants were quantified using the Cell Quest Pro software. F, Cell cycle analysis 
of NCCIT-R cells treated with MonA for 48 h. The amount of apoptotic cells (sub-G1 population) was quantified using the Cell Quest Pro 
software.
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as DNA fragmentation were detected by flow cytometry 
(Fig. 2E, 2F). Note that a significant number of necrotic 
cells was observed (Fig. 2E, 2F).
Monanchocidin A induces unselective protein 
degradation
Cisplatin induces cell death via mitogen-activated 
protein kinases (MAPK) [18]. Therefore, we examined the 
effect of MonA on the activity of three main MAPK. A 
concentration of 50 µM of MonA was used to get a more 
pronounced effect. Activation of p38 and ERK, but not 
JNK was detected (Fig. 3A). Degradation of different 
proteins was observed in NCCIT-R cells both after 
short term exposure to high doses of MonA (30 µM - 50 
µM), as well as after long-term exposure to low doses 
of MonA (0.5 µM - 2 µM) (Fig. 3B, 3C). Surprisingly, 
the degradation was observed not only for MAPK (total 
p38, JNK, and ERK, Fig. 3A), but also for various and 
unrelated long-lived proteins such as α-tubulin and β-actin 
(Fig. 3B). In addition, significant changes in the protein 
patterns were observed on polyacrylamide gels stained 
with colloidal Coomassie Blue after PAGE. Intensive 
spots occurred at the lower end of the gel in the area where 
low molecular weight proteins are located (Fig. 3C). 
We suspect that these changes are caused by protein 
degradation induced by the compound. To assess the 
composition of the spot, we performed tandem mass 
spectrometry analysis of two samples picked from the 
gel area with Mw ~5 kDa, both from the upper and 
lower end of the spot (Fig. 3C). Several proteins were 
identified. Interestingly, all of these peptides were parts 
of “mother” proteins of higher molecular weight (11 – 
80 kDa) (see supplementary, Table S2). Therefore, we 
assume unselective protein degradation due to MonA 
exposure. Notably, this protein degradation occurs before 
the initiation of apoptosis. Thus, it does not depend on 
classical apoptosis (Fig. 3D). It is important to note, that 
non-malignant HEK 298T cells, treated with MonA for 48 
h did not reveal any signs of protein degradation (Fig. 3E)
Unselective protein degradation by MonA is 
autophagy-dependent
Various processes can induce protein degradation, 
which must be considered a lethal cellular event. 
Therefore we investigated the role of potential proteolytic 
pathways: NCCIT-R cells were pretreated with different 
inhibitors, including the pan-caspase inhibitor z-VAD-
fmk, the autophagy inhibitor 3-methyladenine (3-MA), the 
lysosome inhibitor NH4Cl, the calpain inhibitor calpeptin, 
the protease inhibitor leupeptin, and a cocktail of several 
protease inhibitors (see Materials and Methods) before 
exposure to MonA. Potential antagonism was analyzed by 
the Chou-Talalay method [19, 20]. The most pronounced 
antagonistic effect against MonA was observed with 3-MA 
pretreatment. Consequently, autophagy was suspected to 
mediate the cytotoxic effect of MonA in NCCIT-R cells 
(Fig. 4A). Therefore, we analyzed expression levels of 
LC3B-II - a marker of autophagy [21, 22]. We found 
an up-regulation of LC3B-II in NCCIT-R cells both 
after long-term exposure to low concentrations (0.25 
µM – 2 µM), and after short-term exposure to high 
concentrations (20 µM – 50 µM) of MonA (Fig. 4B). In 
addition, formation of autophagic vacuoles was observed 
by electronic microscopy (Fig. 4C). Finally, pre-treatment 
with 3-MA was able to suppress MonA induced protein 
degradation in Western blotting and PAGE analyses 
(Fig. 4D). However, pre- and co-treatment with 3-MA 
did not abolish protein degradation induced by MonA at 
concentrations > 2µM (48 h of treatment). Thus, MonA 
exerts a different mode of action at high concentrations 
and long exposure times.
The up-regulation of LC3B-II was also observed 
in postate cancer cells treated with MonA, suggesting 
that autophagy is a general mechanism underlying the 
cytotoxic mode of action of MonA in cancer cells (Fig. 
4E).
Classical cytotoxic agents do not induce 
autophagy
To assess whether induction of autophagy is a 
common phenomenon under substances known to induce 
classical apoptosis, we treated NCCIT-R cells with 
docetaxel, anisomycin, and cisplatin for 48 h. None of 
the drugs revealed an up-regulation of LC3B-II, while an 
increase of markers of apoptosis e.g. cleavage of PARP 
and caspase-3 were observed (Fig. 5A). In line with these 
observations, MonA-treated cells exhibited a different 
morphology (cell rounding, cytoplasm vacuolization) 
compared to cisplatin treated cells (cell shrinkage, 
membrane blebbing, apoptotic bodies formation) (Fig. 
5B).
Monanchocidin A induces lysosomal membrane 
permeabilization (LMP) at high concentrations
3-MA did not inhibit rapid and unspecific protein 
degradation in NCCIT-R cells treated with MonA at high 
concentrations. Permeabilization of the membranes of 
lysosomes, unlashing the proteolytic activity of lysosomal 
proteases may be underlying this observation. In contrast 
to other metabolic processes, LMP can start shortly after 
exposure to a specific compound and thus results in a 
rapid protein degradation [23]. In order to evaluate if 
this is the case for MonA, we used the lysosomotropic 
metachromatic fluorochrome dye acridine orange 
(AO) to track the integrity of lysosomes. When excited 
with blue light, AO emits red fluorescence at high 
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Figure 3: Effect of MonA on activation of MAPK and protein degradation. A, NCCIT-R cells were analyzed after treatment 
with MonA for 1 h by Western blotting. Cells treated with 50 µM of anisomycin for 1 h (Aniso) were used as a positive control for MAPK 
activation. B, Protein analysis by Western blotting reveals degradation of proteins induced by MonA following short- and long-term 
treatment. Cells treated with 10 μM of cisplatin-treated (CP) for 48 h do not show signs of protein degradation. C, Analysis of NCCIT-R 
cells treated with 1 µM of MonA for 1 h. After treatment, cells were harvested and proteins were separated using PAGE on 15% acrylamide 
gels. The proteins from the upper part of the gel (containing proteins with Mw > 15 kDa) were transferred to a PVDF membrane followed 
by Coomassie Blue staining of the gel. The lower part of the gel was stained with Coomassie Blue without transfer stage. Two samples 
of the spot were randomly picked from the area between ~5 kDa and ~1 kDa, followed by trypsination and identification of peptides by 
tandem mass spectrometry. D, Analysis of NCCIT-R cells treated with 20 µM of MonA for 1-3 h. Cleavage of PARP and caspase-3 were 
investigated as hallmarks of apoptosis. Cells treated with 10 μM of cisplatin (CP) for 48 h were used for comparison of the effects of a 
classical cytotoxic agent. E, Analysis of non-malignant HEK 293T cells treated with 0.0625 – 1 µM of MonA for 48 h. Cells were harvested 
and proteins were separated using PAGE on 15% acrylamide gels. The proteins from the upper part of the gel were transferred to a PVDF, 
while the lower part of the gel (containing proteins with Mw < 15 kDa) was stained with Coomassie Blue without transfer stage.
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Figure 4: Protein degradation induced by MonA shows hallmarks of autophagy. A, The effect of specific inhibitors on the 
survival of NCCIT-R cells treated with MonA was examined using the MTT assay. Co-treatment of MonA and the indicated inhibitors for 
48 h was performed. The combinational index (CI) values were calculated with the CompuSyn software for the Fa (fraction affected) = 
0.5. Concentration ratios of the substances used are shown in the supplementary (Table S3). B, Protein expression of LC3B-II, a marker of 
autophagy, in NCCIT-R cells following treatment with MonA at the indicated concentrations and timespans. C, Representative electronic 
microscopy pictures of NCCIT-R cells treated with 2 µM of MonA for 48 h in comparison to untreated control cells (0 µM). The number 
and size of autophagosomes (indicated by arrows) significantly increases after treatment. D, Analysis of NCCIT-R cells treated with 1 
µM or 2 µM of MonA for 48 h with or without an inhibitor of autophagy, 3-MA. After treatment, cells were harvested and proteins were 
separated using PAGE on 15% acrylamide gels. The proteins from the upper part of the gel (containing proteins with Mw > 15 kDa) were 
transferred to a PVDF membrane followed by Coomassie Blue staining of the gel. The lower part of the gel was stained with Coomassie 
Blue without transfer step. E, Protein expression of LC3B-II, a marker of autophagy, in prostate cancer cells following treatment with 
MonA at the indicated concentrations for 48 h.
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concentrations (when localized in intact lysosomes) and 
green fluorescence at low concentrations (when present 
in the cytosol and the nucleus, for example after LMP) 
[24, 25]. We observed disappearance of red fluorescence 
coupled with increased green fluorescence, indicative for 
LMP induced by high concentrations of MonA (Fig. 6A). 
A similar effect on NCCIT-R cells was observed with 
chloroquine (CQ), a substance known to induce LMP [25, 
26]. Further evidence for the induction of LMP was the 
release of cathepsin B into the extracellular space, which 
occurred upon treatment with MonA at concentrations of 
2 µM or higher (Fig. 6B).
DISCUSSION
MonA is a novel marine compound derived from the 
marine sponge Monanchora pulchra. MonA effectively 
inhibits the growth of human leukemia cell lines HL-
60 and THP-1, presumably by induction of apoptosis 
[15]. However, to date, efficacy and mode of action of 
MonA in solid tumors remain elusive. We were able to 
show that MonA exerts high cytotoxicity in human GCT, 
prostate cancer, and bladder cancer cell lines. In contrast, 
non-malignant human cells were less sensitive to the 
compound. Remarkably, we found equal activity of the 
marine compound in castration-resistant and hormone-
sensitive prostate cancer cell lines, as well as in cisplatin-
resistant and -sensitive GCT cell lines, suggesting that 
MonA is active even if standard treatment regimens fail.
MonA induced programmed cell death and a G1- 
and S-phase cell cycle arrest in GCT cells. However, a 
more detailed examination revealed that not classical 
apoptosis, but autophagy and/or lysosomal membrane 
permeabilization are the major mechanisms leading to 
cell death. 
Macroautophagy (referred to as autophagy in the 
following) is the basic cellular catabolic process of non-
selective bulk degradation of damaged or long-lived 
proteins, organelles or/and cytoplasm by lysosomes 
[27-29]. It results from cellular stress, e.g. nutrient 
deprivation [30], and includes the formation of double-
membrane vesicles (autophagosomes), cytoplasmic 
constituents engulfing and finally fusing with lysosomes, 
leading to degradation and recycling of sequestered 
contents [28]. However, the role of autophagy in tumor 
Figure 5: Effect of cytotoxic compounds on NCCIT-R cells. A, NCCIT-R cells were treated with docetaxel, anisomycin, or 
cisplatin for 48 h. The effect on markers of apoptosis (cleavage of PARP and caspase-3) and autophagy (LC3B-II) were analyzed using 
Western blotting. While all show induction of apoptosis, expression of LC3B-II is not increased after treatment with these substances. B, 
Microphotographs of NCCIT-R cells treated with cisplatin or MonA for 48 h show morphological changes induced by the substances. The 
pictures were made at x100 magnification. Each bar represents 50 µm.
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growth and suppression is controversial. In fact, opposite 
activity has been observed depending on different cell 
types and stimuli [30]. Autophagy has been found to be 
cytoprotective, cytotoxic, cytostatic, or even without any 
effect on cell survival [30-32]. However, the antitumor 
effects of several drugs, such as tyrosine kinases or mTOR 
inhibitors (for review see [28]) involve the induction of 
cytotoxic autophagy, also called type II programmed cell 
death [33]. 
In fact, unspecific degradation of various proteins 
occurred in our analyses following short-term treatment 
with high concentrations, or long-term treatment with 
low concentrations of MonA. Remarkably, protein 
degradation induced by long-term treatment could be 
inhibited by the selective autophagy inhibitor 3-MA [34]. 
In addition, autophagic vacuole formation after exposure 
to low concentrations of MonA and the up-regulation of 
the autophagy marker LC3B-II strongly suggest that the 
compound is an inductor of autophagy. In contrast, other 
cytotoxic substances such as docetaxel, or cisplatin, did 
not induce an up-regulation of LC3B-II in NCCIT-R. Thus, 
as expected, apoptosis, but not autophagy, is the central 
mechanism of action of these substances. Observation 
of hallmarks of apoptosis following MonA treatment is 
assumed to be a secondary event [23], because they appear 
after, but not simultaneously with protein degradation.
Figure 6: Induction of lysosomal membrane permeabilization (LMP) and model of the suggested mechanism of action 
of MonA. A, NCCIT-R cells were treated for with chloroquine (CQ, positive control for lysosomal membrane permeabilization) or MonA 
for 1 h, stained with acridine orange and DAPI, and immediately analyzed using fluorescent microscopy. Intact lysosomes were observed 
as organelles emitting red fluorescence (indicated by arrows). Red fluorescence was quantified using Image J software and is graphically 
depicted by column bars. B, Cells were treated with MonA for 48 h, and immobilized on glass plates. Samples were permeabilized, 
blocked, labeled with a primary anti-cathepsin B antibody, followed by a secondary Alexa Fluor 488-conjugated antibody labeling, and 
analyzed using fluorescent microscopy. Release of cathepsin B into the extracellular space was observed in cells treated with MonA. The 
microphotographs (A, B) were made at x400 and x100 magnifications. Each bar represents 50 µm. C, Model of the suggested mechanism 
of action of MonA in NCCIT-R cells.
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At high concentrations > 2 µM, the dominating 
mechanism of protein degradation (and therefore 
of cell death) of MonA was lysosomal membrane 
permeabilization (LMP). During LMP, cathepsins and 
other hydrolases are released from the lysosomal lumen 
into the cytosol, leading to unselective degradation of 
cellular components [25]. LMP is a potentially lethal 
event, because the presence of lysosomal proteases in the 
cytosol causes digestion of vital proteins and the activation 
of caspases and other hydrolases [35, 36]. However, cell 
death resulting from massive LMP can also show necrosis-
like features and be caspase-independent [25, 37]. In our 
experiments, we found loss of lysosomal integrity as well 
as release of cathepsin B into extracellular space in cells 
treated with ≥ 2 µM MonA, supporting the idea of LMP 
induction. 
Inhibitors of lysosomal activity and proteases were 
able to inhibit the cytotoxic effect of MonA to a certain 
degree. This also suggests that autophagy and induction 
of LMP are relevant for MonA activity, as both processes 
require active lysosoms and cathepsins. The moderate 
antagonistic effect of the pan-caspase inhibitor z-VAD-
fmk indicates caspases activation, most likely as a rather 
late event. Caspase activation could result from direct 
cleavage of caspases by cathepsins, or be an indirect 
down-stream effect of autophagy and/or LMP. It should 
be noted that z-VAD-fmk can also inhibit other cysteine 
proteases including several cathepsins [38], which - at 
least in part - explains the antagonistic effect of z-VAD-
fmk in MonA-treated cells.
Interestingly, induction of autophagy as the 
mechanism underlying cytotoxicity has never been 
reported before in GCT cells, while its induction in 
prostate cancer and bladder cancer cells is a known and 
well characterized phenomenon. It is induced by a number 
of anticancer drugs such as rapamycin, everolimus, 
metformin, and neuregulin (for review see [33, 39]). In our 
experiments, we have observed the induction of autophagy 
in both GCT and prostate cancer cells treated with MonA. 
As the mechanism of action of MonA strongly differs 
from standard agents used to treat these tumors [40], 
MonA might be a promising new substance capable of 
overcoming resistance against currently applied therapies 
[23, 33]. In addition, MonA may be able to enhance the 
activity of cisplatin in GCT cells, as synergistic effects 
were observed when cisplatin and MonA were combined 
in NCCIT-R cells. This is in line with the previous findings 
that LMP can promote and increase induction of apoptosis 
[35].
In conclusion, MonA is a highly effective marine 
compound, which holds promise of therapeutic activity 
in genitourinary cancers even if standard therapies fail. 
This is most likely due the distinct different mechanism 
of action when compared to standard chemotherapies, 
namely drug-induced autophagy and LMP.
MATERIALS AND METHODS
Reagents and antibodies
The marine alkaloid monanchocidin A (MonA) was 
isolated from the marine sponge Monanchora pulchra 
as previously described [15]. Anisomycin, docetaxel (10 
mg/ml) and cisplatin (cis-diamminedichloroplatinum 
(II), 1 mg/ml) were purchased from NeoCorp (Weilheim, 
Germany), acridine orange and calpeptin from Sigma 
(Taufkirchen, Germany), MG-132 from Calbiochem 
(Darmstadt, Germany), NH4Cl and Coomassie brilliant 
blue G 250 from Carl Roth (Karlsruhe, Germany), 
3-methyladenine and z-VAD(OMe)-fmk (referred here 
as z-VAD-fmk) from Enzo Life Sciences (Farmingdale, 
NY, USA), leupeptin from Serva (Heidelberg, Germany), 
protease inhibitors cocktail (cOmplete Mini EDTA-
free) from Roche (Munnheim, Germany). Primary and 
secondary antibodies used are listed in the supplementary.
Cell lines and culture conditions
The human prostate cancer cell lines PC3 
(docetaxel resistant, androgen-independent), DU145 
(docetaxel sensitive, androgen-independent), LNCaP 
(docetaxel sensitive, androgen-dependent) [41, 42], 
human bladder cancer cell lines RT112, RT4, 486p, T24, 
human embryonic kidney cell line HEK 293T, human 
embilical vascular endothelium cell line HUVEC, as 
well as human fibroblast cell lines MRC-5 and MRC-9 
were obtained from ATCC (Manassas, VA, USA). The 
human germ cell tumor cancer cell line NCCIT was 
obtained from DSMZ (Braunschweig, Germany). TCam-
2 and 2102EP cells were kindly provided by Prof. L. 
Looijenga (Rotterdam, The Netherlands). The cisplatin-
resistant sublines NCCIT-R and 2102EP-R have been 
generated as reported before [16, 17]. Cells were cultured 
according to the manufacturers instructions (culture 
conditions are described in the supplementary). Cells 
were continuously kept in culture for a maximum of 3 
months, and were routinely inspected microscopically for 
stable phenotype and regularly checked for contamination 
with mycoplasma. Cell line authentication was performed 
by DSMZ (Braunschweig, Germany) using highly 
polymorphic short tandem repeat loci.
In vitro MTT-based drug sensitivity assay
The in vitro cytotoxicity of individual substances 
and drug combinations was evaluated using the MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay, which was performed as previously 
described [43].
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Examination of synergistic/antagonistic effect of 
drug combination 
Determination of synergistic or antagonistic drug 
effects in combination assays was performed using the 
Chou-Talalay method [20]. Data were generated by MTT 
assay. The combinational index (CI) was calculated for the 
constant drugs ratio with the CompuSyn v.1.0. software 
(ComboSyn, Inc., Paramus, NJ, USA). Synergism is 
defined as a CI < 1, whereas antagonism is defined 
by a CI > 1. The MTT assay was used to examine the 
combination of MonA at the IC50 with defined inhibitors 
of autophagy or LMP, or with the IC50 of cisplatin. Doses 
of the drugs used for combination treatment are shown 
in the supplementary (Table S3). All experiments were 
performed in triplicates and were repeated at least three 
times.
In vitro trypan blue-based viability assay
The in vitro effect of MonA on cell viability was 
evaluated by trypan blue exclusion assay using semi-
automated cell count with a Beckman Coulter Vi-CELL 
(Beckman Coulter, Krefeld, Germany) as described before 
[43].
Protein preparation and western blotting
Preparation of protein extracts and Western 
blotting were performed as described previously with 
slight modifications [44]. In brief, 1 × 106 cells/well 
were seeded in Petri dishes (ø 6 cm, 5 mL/dish). Cells 
were harvested, proteins were extracted, subjected to 
electrophoresis in 10-15% SDS-polyacrylamide gels at 
120 V, and transferred from gel to a 0.2 µm pore PVDF 
membrane. The membrane was blocked and incubated 
with the primary antibody according to the manufacturer’s 
protocol (for antibodies used, see the supplementary). 
After washing, the membranes were incubated with the 
corresponding secondary antibody for 1 h at RT. Signals 
were detected using the ECL chemiluminescence system 
(Thermo Scientific, Rockford, IL, USA) according to the 
manufacturer’s protocol.
Staining of the SDS-polyacrylamide gels with 
Coomassie brilliant blue
SDS-polyacrylamide gels were prepared as 
described above. Dye-free loading buffer was used for the 
protein samples preparation. Gels were fixed and stained 
with colloidal Coomassie Blue overnight, destained, and 
digitalized as previously described [45]. 
Protein identification by mass spectrometry
Protein spots of interest were excised from the gel 
and digested manually with trypsin. Mass spectrometry 
measurements and identification were performed as 
previously described [46]. The peptide solutions were 
analyzed using a Proxeon nano-LC system equipped 
with a nano-ESI source (Proxeon, Odense, Denmark) 
connected to a LTQ-Orbitrap-MS (ThermoElectron, 
Bremen, Germany). For protein identification, automated 
database searches using the Sequest algorithm rel. 27.11 
(Sorcerer built 4.05, Sage-N Research Inc., Milpitas, CA) 
were performed using a Swiss-Prot database rel. 2013_10 
(limited to human entries). The considered enzyme 
specificity was fully tryptic. Parent mass tolerance (MS) 
was set to 10 ppm and fragment mass tolerance 1 Da. 
Methionine oxidation and propionamid were considered 
as optional modification. Protein identification was based 
on a) peptide length of 5, peptide probability: 95.0% 
minimum and sequest: deltaCn scores of greater than 
0.1 and XCorr scores of greater than 2.3, 3.8 and 3.8 
for doubly, triply, and quadruply charged peptides and 
b) protein thresholds: 95.0% minimum and 3 peptides 
minimum.
Detection of apoptotic cells by annexin-V-FITC / 
PI double staining
Induction of apoptosis was examined using FACS-
based analysis with an annexin-V-FITC (BD Bioscience, 
San Jose, CA, USA) and propidium iodide (PI) (Sigma) 
double staining. The experiment was performed as 
previously described [47].
Cell cycle analysis
The cell cycle distribution was analyzed by flow 
cytometry using PI staining as described before [45] with 
slight modifications. In brief, cells were pre-incubated 
overnight in 6-well plates (2 × 105 cells/well). The 
medium was changed to 0.1% FBS/DMEM medium 
(DMEM/GlutamaxTM-I medium containing 0.1% FBS 
and 1% penicillin/streptomycin). After 24 h of incubation, 
the medium was changed to normal 10% FBS/DMEM 
medium containing different concentrations of the 
substances examined. After 24 h of treatment, cells were 
harvested with a trypsin-EDTA solution, fixed, stained, 
and analyzed. The results were quantitatively analyzed 
using the FlowJo software, v.7 (Treestar Inc, Ashland, 
OR, USA).
Oncotarget17339www.impactjournals.com/oncotarget
Detection of activated caspase-3 by FACS
To assess occurrence of caspase-3 cleavage, FACS-
based analysis with a cleaved caspase-3 specific, PE-linked 
antibody (BD Bioscience) was used. NCCIT-R cells were 
pre-incubated overnight in 6-well plates (2 x 105 cells/
well). The medium was replaced by a medium containing 
different concentrations of the substances examined. After 
48 h of treatment, cells were harvested with a trypsin-
EDTA solution, washed twice with PBS, and fixated 
with 2% paraformaldehyde (pH 7.4) for 10 min at 37°C. 
After incubation on ice for 1 min, cells were pelleted 
by centrifugation for 5 min at 453 x g, resuspended in 1 
mL of 90% methanol, and incubated for 30 min at 4°C. 
Then 0.5 mL of 0.5% BSA/PBS were added, cells were 
pelleted (10 min at 453 x g), resuspended in 50 µL of 0.5% 
BSA/PBS, and incubated for 10 min at RT. 1 µL of either 
cleaved caspase-3 specific, PE-linked antibody, or PE-
linked isotype control, or PBS were added followed by 
incubation for 60 min at RT in the dark. Afterwards, cells 
were resuspended in 0.5 mL of 0.5% BSA/PBS, pelleted 
(10 min at 453 x g), resuspended in 0.3 mL of PBS, and 
analyzed using the FACS Calibur (BD Bioscience). The 
results were analyzed using the BD Bioscience Cell Quest 
Pro software (BD Bioscience).
Light microscopy
Microphotographs of cells were taken using 
Axiovert 25 microscope and an AxioCam MRc camera 
(Carl Zeiss, Göttingen, Germany) at x400 magnification.
Electronic microscopy
For electron microscopy, untreated and treated 
NCCIT-R cells were fixed using glutaraldehyde and 
embedded in Epon-Araldite. Then, semithin and ultrathin 
sections were cut and analysed using a Zeiss microscope 
EM 906 (Carl Zeiss, Oberkochen, Germany) at various 
magnifications.
Acridine orange staining of lysosomes
NCCIT-R cells were pre-incubated overnight in 
8-chamber glass slides (5 x 104 cells/chamber). The 
medium was changed with medium containing different 
concentrations of the substances examined, and cells were 
treated for 60 min. Then cells were washed twice with PBS 
solution, stained with 0.5 µg/mL of acridine orange/PBS 
for 15 min at 37°C, covered with DAPI-based ProLong® 
Gold reagent (Life Technologies, Eugene, OR, USA), and 
immediately analyzed with AxioScope.A1 (Carl Zeiss) 
microscope and with the AxioVision40 V4.8 software 
(Carl Zeiss Imaging Solutions, Göttingen, Germany). 
Red fluorescence measurements and quantification were 
performed with Image J software (NIH, Bethesda, USA).
Detection of cathepsin B release
To assess release of cathepsin B into the 
extracellular space, NCCIT-R cells were pre-incubated 
overnight in 6-well plates (2 x 105 cells/well), and were 
then treated with MonA for 48 h. After trypsination, cells 
were immobilized on glass slides using the cytospin 
method and dried overnight. Cells were fixed with 2% 
(w/v) PFA/PBS, washed with PBS and permeabilized with 
0.1% (v/v) Triton X-100 solution in 2% (v/v) normal goat 
serum/PBS for 30 min. After washing with PBS, samples 
were treated with 1:400 rabbit anti-cathepsin B antibody 
solution (in 0.1% (w/v) NaN3; 0.2% (w/v) BSA in PBS, 
pH 7.4) overnight at 4°C, washed with PBS and incubated 
with secondary anti-rabbit Alexa Fluor 488-conjugated 
antibody solution in PSB for 1 h at RT. Then, samples 
were washed with PBS, covered with DAPI-based 
ProLong® Gold reagent (Life Technologies) and directly 
analyzed with AxioScope.A1 (Carl Zeiss) microscope and 
with the AxioVision40 V4.8 software (Carl Zeiss Imaging 
Solutions).
Statistical analysis
Statistical analyses were performed using GraphPad 
Prism software v. 5.01 (GraphPad Prism software Inc., 
La Jolla, CA, USA). Data are presented as mean ±SEM 
(standard error of the mean). All the experiments were 
performed in triplicates and repeated at least three times. 
The unpaired Student’s t-test was used for comparison of 
two groups. Differences were considered to be statistically 
significant if p < 0.05.
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